Time:April 11-12, 2017
Country&Region:Shanghai, Shanghai, China Mainland
Venue:Shanghai China
Organizer:Shine Consultant
Asia Pharma R&D Leaders 2017 is designed to be a premium strategic platform for big pharmas, biotechs, academia and other stake holders in pharma industry to meet, communicate and establish partnership on pharma R&D. Leading executives from the industry will discuss key topics from global R&D trends, development strategies, Innovation capability building to collaboration opportunities. Besides the extensive knowledge and practical experience, you will also gain incredible value through the customized 1-2-1 meetings during the event. This summit will leave you with a wealth of knowledge contacts and help you to optimize R&D strategy in Asia for the next 12 months.
Key Issues
Sustaining the new golden age for drug development
Addressing challenges in the ever-changing regulatory and marketing environment
Building Global R&D Strategy for China pharma industry
Cross-border transaction: challenges and strategies
Building a strategic platform for sustainable innovation
How to make the right R&D strategy to get high ROI
Exploring global tech-transfer trends and future collaboration opportunities
Examining the future trends and challenges for Clinical development in China
Cutting-edge targets discovery for new drug development
Constructing world-class R&D eco-system through external collaboration
challenges and opportunities for immuno-oncology therapy
Establishing alliance between industry and academia to accelerate drug innovation
Who Will Attend? By industry:
Pharmas
biotechs
Academia/Research institute
CROs/CMOs
Venture Capitals/Funds
Law Firms/Consultants
Bio clusters
Other vendors
By titles:
CEO, President, Vice President/Director of
R&D, BD, Clinical, Discovery, Licensing, Partnering, alliance management, external research, commercialization
Tel:+86 2152428128
Website:http://aprdl.shine-consultant.com/showpage.aspx?id=6140
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: